Relay Therapeutics (RLAY) Goldman Sachs 45th Annual Global Healthcare Conference summary

Platform overview and strategic focus

• Dynamo platform integrates experimental and computational tools to improve drug development efficiency and effectiveness, targeting low-risk clinical and biological opportunities.

• Focus areas include precision oncology, genetic diseases, and vascular malformations, all with significant market potential and validated targets.

• Business development emphasizes integrating new technologies, such as big data and machine learning, while prioritizing internal asset advancement.

• The platform's evolution is ongoing, with a high threshold for acquiring new platform assets.

Clinical pipeline and upcoming milestones

• Key upcoming data: PI3K alpha mutant selective inhibitor (RLY-2608) in breast cancer, with robust data expected in the second half of the year.

• At least 40 patients at 600 mg BID with six months follow-up will be included, aiming to show clear efficacy and safety differentiation.

• FGFR2 inhibitor program update and regulatory interaction planned for the second half of the year.

• Vascular malformations program to enter clinic in Q1 next year; Fabry and NRAS programs to follow in the second half of next year.

PI3K alpha franchise and breast cancer strategy

• Three pillars: breast cancer (multiple lines and combinations), vascular malformations, and other solid tumors, each representing major commercial opportunities.

• RLY-2608 positioned as a safer, more tolerable alternative to current non-selective inhibitors, with potential to move into earlier treatment lines.

• Clinical trial collaboration with Pfizer to combine RLY-2608 with their selective CDK4 inhibitor, aiming to initiate by year-end.